Advertisement

Breast Cancer Research and Treatment

, Volume 171, Issue 1, pp 161–171 | Cite as

SNP rs2071095 in LincRNA H19 is associated with breast cancer risk

  • Ping Cui
  • Yanrui Zhao
  • Xinlei Chu
  • Na He
  • Hong Zheng
  • Jiali Han
  • Fengju Song
  • Kexin Chen
Epidemiology
  • 159 Downloads

Abstract

Purpose

An increasing number of long intergenic non-coding RNAs (lincRNAs) appear to play critical roles in cancer development and progression. To assess the association between SNPs that reside in regions of lincRNAs and breast cancer risk, we performed a large case-control study in China.

Methods

We carried out a two-stage case-control study including 2881 breast cancer cases and 3220 controls. In stage I, we genotyped 17 independent (r2 < 0.5) SNPs located in 6 tumor-related lincRNAs by using the TaqMan platform. In stage II, SNPs potentially associated with breast cancer risk were replicated in an independent population. Quantitative real-time PCR was used to measure H19 levels in tissues from 228 breast cancer patients with different genotypes.

Results

We identified 2 SNPs significantly associated with breast cancer risk in stage I (P < 0.05), but not significantly replicated in stage II. We combined the data from stage I and stage II, and found that, compared with the rs2071095 CC genotype, AA and CA + AA genotypes were associated with significantly decreased risk of breast cancer (adjusted OR 0.83, 95% CI 0.69–0.99; adjusted OR 0.88, 95% CI 0.80–0.98, respectively). Stratified analyses showed that rs2071095 was associated with breast cancer risk in estrogen receptor (ER)-positive patients (P = 0.002), but not in ER-negative ones (P = 0.332). Expression levels of H19 in breast cancer cases with AA genotype were significantly lower than those with CC genotype.

Conclusions

We identified that rs2071095 may contribute to the susceptibility of breast cancer in Chinese women via affecting H19 expression. The mechanisms underlying the association remain to be investigated.

Keywords

Breast cancer H19 LincRNA Genetic susceptibility SNP 

Notes

Acknowledgements

This study was supported by the National Natural Science Foundation of China (No.81473039), and the Science & Technology Development Fund of Tianjin Education Commission for Higher Education (No.20140141).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

We declare that all experiments that we have performed comply with the current laws of our country. All procedures performed in our study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132CrossRefPubMedGoogle Scholar
  2. 2.
    Pennisi E (2011) The Biology of Genomes. Disease risk links to gene regulation. Science 332:1031CrossRefPubMedGoogle Scholar
  3. 3.
    Zheng J, Huang X, Tan W et al (2016) Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. Nat Genet 48:747–757CrossRefPubMedGoogle Scholar
  4. 4.
    Kumar V, Westra HJ, Karjalainen J et al (2013) Human disease-associated genetic variation impacts large intergenic non-coding RNA expression. PLoS Genet 9:e1003201CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cabili MN, Trapnell C, Goff L et al (2011) Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 25:1915–1927CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Iyer MK, Niknafs YS, Malik R et al (2015) The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 47:199–208CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Geisler S, Coller J (2013) RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol 14:699–712CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Khalil AM, Guttman M, Huarte M et al (2009) Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 106:11667–11672CrossRefPubMedGoogle Scholar
  9. 9.
    Rinn JL, Kertesz M, Wang JK et al (2007) Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 129:1311–1323CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Nagano T, Mitchell JA, Sanz LA et al (2008) The Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science 322:1717–1720CrossRefPubMedGoogle Scholar
  11. 11.
    Guttman M, Donaghey J, Carey BW et al (2011) lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 477:295–300CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Gupta RA, Shah N, Wang KC et al (2010) Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464:1071–1076CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Bhan A, Soleimani M, Mandal SS (2017) Long noncoding RNA and cancer: a new paradigm. Cancer Res 77:3965–3981CrossRefPubMedGoogle Scholar
  14. 14.
    Bhan A, Hussain I, Ansari KI et al (2013) Antisense transcript long noncoding RNA (lncRNA) HOTAIR is transcriptionally induced by estradiol. J Mol Biol 425:3707–3722CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Huarte M, Guttman M, Feldser D et al (2010) A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 142:409–419CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Bayram S, Sumbul AT, Batmaci CY et al (2015) Effect of HOTAIR rs920778 polymorphism on breast cancer susceptibility and clinicopathologic features in a Turkish population. Tumour Biol 36:3863–3870CrossRefPubMedGoogle Scholar
  17. 17.
    Peng R, Luo C, Guo Q et al (2018) Association analyses of genetic variants in long non-coding RNA MALAT1 with breast cancer susceptibility and mRNA expression of MALAT1 in Chinese Han population. Gene 642:241–248CrossRefPubMedGoogle Scholar
  18. 18.
    Huang NS, Chi YY, Xue JY et al (2016) Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer. Oncotarget 7:37957–37965PubMedPubMedCentralGoogle Scholar
  19. 19.
    Timofeeva MN, Hung RJ, Rafnar T et al (2012) Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet 21:4980–4995CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Royds JA, Pilbrow AP, Ahn A et al (2015) The rs11515 polymorphism is more frequent and associated with aggressive breast tumors with increased ANRIL and decreased p16 (INK4a) expression. Front Oncol 5:306PubMedGoogle Scholar
  21. 21.
    Riaz M, Berns EM, Sieuwerts AM et al (2012) Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes. Breast Cancer Res Treat 133:843–851CrossRefPubMedGoogle Scholar
  22. 22.
    Song F, Zheng H, Liu B et al (2009) An miR-502-binding site single-nucleotide polymorphism in the 3′-untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin Cancer Res 15:6292–6300CrossRefPubMedGoogle Scholar
  23. 23.
    Bartolomei MS, Zemel S, Tilghman SM (1991) Parental imprinting of the mouse H19 gene. Nature 351:153–155CrossRefPubMedGoogle Scholar
  24. 24.
    Seidl CI, Stricker SH, Barlow DP (2006) The imprinted Air ncRNA is an atypical RNAPII transcript that evades splicing and escapes nuclear export. EMBO J 25:3565–3575CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Brannan CI, Dees EC, Ingram RS et al (1990) The product of the H19 gene may function as an RNA. Mol Cell Biol 10:28–36CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Adriaenssens E, Dumont L, Lottin S et al (1998) H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression. Am J Pathol 153:1597–1607CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Gabory A, Jammes H, Dandolo L (2010) The H19 locus: role of an imprinted non-coding RNA in growth and development. Bioessays 32:473–480CrossRefPubMedGoogle Scholar
  28. 28.
    Cai X, Cullen BR (2007) The imprinted H19 noncoding RNA is a primary microRNA precursor. RNA 13:313–316CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kallen AN, Zhou XB, Xu J et al (2013) The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell 52:101–112CrossRefPubMedGoogle Scholar
  30. 30.
    Barsyte-Lovejoy D, Lau SK, Boutros PC et al (2006) The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res 66:5330–5337CrossRefPubMedGoogle Scholar
  31. 31.
    Ariel I, Sughayer M, Fellig Y et al (2000) The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol Pathol 53:320–323CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Sorin V, Ohana P, Gallula J et al (2012) H19-promoter-targeted therapy combined with gemcitabine in the treatment of pancreatic cancer. ISRN Oncol 2012: 351750Google Scholar
  33. 33.
    Adriaenssens E, Lottin S, Dugimont T et al (1999) Steroid hormones modulate H19 gene expression in both mammary gland and uterus. Oncogene 18:4460–4473CrossRefPubMedGoogle Scholar
  34. 34.
    Basak P, Chatterjee S, Weger S et al (2015) Estrogen regulates luminal progenitor cell differentiation through H19 gene expression. Endocr Relat Cancer 22:505–517CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Guo H, Ahmed M, Zhang F et al (2016) Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat Genet 48:1142–1150CrossRefPubMedGoogle Scholar
  36. 36.
    Maurano MT, Humbert R, Rynes E et al (2012) Systematic localization of common disease-associated variation in regulatory DNA. Science 337:1190–1195CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Huang Q, Whitington T, Gao P et al (2014) A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding. Nat Genet 46:126–135CrossRefPubMedGoogle Scholar
  38. 38.
    Zhang X, Cowper-Sal LR, Bailey SD et al (2012) Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus. Genome Res 22:1437–1446CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Cowper-Sal LR, Zhang X, Wright JB et al (2012) Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat Genet 44:1191–1198CrossRefGoogle Scholar
  40. 40.
    Stacey SN, Sulem P, Masson G et al (2009) New common variants affecting susceptibility to basal cell carcinoma. Nat Genet 41:909–914CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Iacobucci I, Sazzini M, Garagnani P et al (2011) A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia. Leuk Res 35:1052–1059CrossRefPubMedGoogle Scholar
  42. 42.
    Healy J, Belanger H, Beaulieu P et al (2007) Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia. Blood 109:683–692CrossRefPubMedGoogle Scholar
  43. 43.
    Cunnington MS, Santibanez KM, Mayosi BM et al (2010) Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression. PLoS Genet 6:e1000899CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Motterle A, Pu X, Wood H et al (2012) Functional analyses of coronary artery disease associated variation on chromosome 9p21 in vascular smooth muscle cells. Hum Mol Genet 21:4021–4029CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Holdt LM, Beutner F, Scholz M et al (2010) ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler Thromb Vasc Biol 30:620–627CrossRefPubMedGoogle Scholar
  46. 46.
    Pasmant E, Sabbagh A, Vidaud M et al (2011) ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J 25:444–448CrossRefPubMedGoogle Scholar
  47. 47.
    Aguilo F, Zhou MM, Walsh MJ (2011) Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. Cancer Res 71:5365–5369CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Kotake Y, Nakagawa T, Kitagawa K et al (2011) Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 30:1956–1962CrossRefPubMedGoogle Scholar
  49. 49.
    Yap KL, Li S, Munoz-Cabello AM et al (2010) Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 38:662–674CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Yu W, Gius D, Onyango P et al (2008) Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 451:202–206CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Lan WG, Xu DH, Xu C et al (2016) Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol Rep 36:263–270CrossRefPubMedGoogle Scholar
  52. 52.
    Zhang EB, Kong R, Yin DD et al (2014) Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget 5:2276–2292PubMedPubMedCentralGoogle Scholar
  53. 53.
    Sun Y, Zheng ZP, Li H et al (2016) ANRIL is associated with the survival rate of patients with colorectal cancer, and affects cell migration and invasion in vitro. Mol Med Rep 14:1714–1720CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy in Ministry of EducationTianjin Medical University Cancer Institute and HospitalTianjinPeople’s Republic of China
  2. 2.Department of Cancer Biobank, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, National Clinical Research Centre of CancerTianjin Medical University Cancer Institute and HospitalTianjinPeople’s Republic of China
  3. 3.Department of Epidemiology, Fairbanks School of Public Health, Indiana University Melvin and Bren Simon Cancer CenterIndiana UniversityIndianapolisUSA

Personalised recommendations